AU2009314335B2 - P70 S6 kinase inhibitor and mTOR inhibitor combination therapy - Google Patents

P70 S6 kinase inhibitor and mTOR inhibitor combination therapy Download PDF

Info

Publication number
AU2009314335B2
AU2009314335B2 AU2009314335A AU2009314335A AU2009314335B2 AU 2009314335 B2 AU2009314335 B2 AU 2009314335B2 AU 2009314335 A AU2009314335 A AU 2009314335A AU 2009314335 A AU2009314335 A AU 2009314335A AU 2009314335 B2 AU2009314335 B2 AU 2009314335B2
Authority
AU
Australia
Prior art keywords
fluoro
trifluoromethyl
phenyl
imidazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2009314335A
Other languages
English (en)
Other versions
AU2009314335A1 (en
Inventor
Gregory Paul Donoho
Sandaruwan Geeganage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2009314335A1 publication Critical patent/AU2009314335A1/en
Application granted granted Critical
Publication of AU2009314335B2 publication Critical patent/AU2009314335B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009314335A 2008-11-11 2009-11-04 P70 S6 kinase inhibitor and mTOR inhibitor combination therapy Expired - Fee Related AU2009314335B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327908P 2008-11-11 2008-11-11
US61/113,279 2008-11-11
PCT/US2009/063188 WO2010056574A1 (en) 2008-11-11 2009-11-04 P70 s6 kinase inhibitor and mtor inhibitor combination therapy

Publications (2)

Publication Number Publication Date
AU2009314335A1 AU2009314335A1 (en) 2010-05-20
AU2009314335B2 true AU2009314335B2 (en) 2013-09-12

Family

ID=41650365

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009314335A Expired - Fee Related AU2009314335B2 (en) 2008-11-11 2009-11-04 P70 S6 kinase inhibitor and mTOR inhibitor combination therapy

Country Status (11)

Country Link
US (1) US20110212977A1 (enExample)
EP (1) EP2355820A1 (enExample)
JP (1) JP2012508239A (enExample)
KR (1) KR20110075014A (enExample)
CN (1) CN102209539B (enExample)
AU (1) AU2009314335B2 (enExample)
BR (1) BRPI0921840A2 (enExample)
CA (1) CA2743242A1 (enExample)
EA (1) EA018824B1 (enExample)
MX (1) MX2011005003A (enExample)
WO (1) WO2010056574A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378500A1 (en) * 2012-02-01 2014-12-25 20/20 Gene Systems, Inc. Methods for predicting tumor reponse to targeted therapies
US9458134B2 (en) 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity
MX2016009135A (es) 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
GB201918815D0 (en) * 2019-12-19 2020-02-05 Imperial College Innovations Ltd Treatment of cancer
AU2021205502A1 (en) * 2020-01-10 2022-07-21 Coimmune, Inc. Methods of treating tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
AU2005322085B2 (en) * 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2007047754A2 (en) * 2005-10-18 2007-04-26 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IKEZOE, T., ET AL., Molecular Cancer Therapeutics, October 2006, Vol. 5, No. 10, pages 2522-2530. *
VAZQUEZ-MARTIN, A., ET AL., Annals of Oncology, June 2008, Vol. 19, No. 6, pages 1097-1109. *

Also Published As

Publication number Publication date
MX2011005003A (es) 2011-05-25
WO2010056574A1 (en) 2010-05-20
JP2012508239A (ja) 2012-04-05
CA2743242A1 (en) 2010-05-20
EA201170681A1 (ru) 2011-10-31
US20110212977A1 (en) 2011-09-01
CN102209539A (zh) 2011-10-05
EP2355820A1 (en) 2011-08-17
AU2009314335A1 (en) 2010-05-20
KR20110075014A (ko) 2011-07-05
CN102209539B (zh) 2013-06-12
EA018824B1 (ru) 2013-10-30
BRPI0921840A2 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
US11638704B2 (en) Bicyclic compounds and their use in the treatment of cancer
US11897871B1 (en) Methods for treating cancer
JP6109161B2 (ja) ヘテロアリール置換ピラゾロピリジン類およびその使用
ES2483726T3 (es) Inhibidores de la P70 S6 quinasa
AU2009314335B2 (en) P70 S6 kinase inhibitor and mTOR inhibitor combination therapy
CA2838784A1 (en) Pyrazolo[3,4-c]pyridine compounds and methods of use
JP2021515767A (ja) Ｅｒｋ５阻害剤の同定及び使用
WO2020005935A1 (en) Glucose uptake inhibitors
EP4370124A1 (en) PI3Ka INHIBITORS AND METHODS OF USE THEREOF
AU2009314336B2 (en) P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
WO2023150394A1 (en) Methods for treatment of cancer
WO2024229444A2 (en) Mutant kras inhibitors and uses thereof
WO2024229442A1 (en) Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer
US11066405B2 (en) Bicyclic compounds and their use in the treatment of cancer
WO2025166230A1 (en) PI3Kα INHIBITORS AND METHODS OF USE THEREOF
EA036060B1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6
WO2025184459A1 (en) Brm and brg1 targeting compounds and associated methods of use
WO2023247596A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application